- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple Myeloma
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 352KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 55KB)
Bortezomib – March 2022
Bortezomib: Solution for Injection 2.5 mg, Solution for Injection 3.5 mg; Bortezomib Ever Pharma®
Last updated
1 July 2022